PLEASANTON, Calif., June 10, 2011 /PRNewswire/ -- Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, announced today that David V. Smith, Executive Vice President and Chief Financial Officer, has resigned from his position in order to pursue other business opportunities. Mr. Smith will remain with Thoratec through July 1st and assist in the transition process.
"Over the past several years, David has played a key role in building a world-class financial infrastructure at Thoratec, which positions the company well to support continued strong performance. We thank him for his contributions and wish him well in his future endeavors," said Gary F. Burbach, President and Chief Executive Officer.
In conjunction with today's announcement, Thoratec is reiterating its previously issued 2011 financial guidance.
Roxanne Oulman, Vice President of Finance, will serve as interim Chief Financial Officer until a permanent replacement is named. Ms. Oulman joined Thoratec in 2004 and has assumed increasing levels of responsibility since that time.
Thoratec is a world leader in therapies to address advanced-stage heart failure. The company's products include the HeartMate® LVAS (Left Ventricular Assist System) and Thoratec® VAD (Ventricular Assist Device) with more than 18,000 devices implanted in patients suffering from heart failure. Thoratec is headquartered in Pleasanton, California. For more information, visit the company's website at http://www.thoratec.com.
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered trademarks of Thoratec Corporation.
Many of the preceding paragraphs, particularly but not exclusively those addressing guidance for fiscal 2011 finan